PrEP, Lube, and the Rectal Mucosa in MSM at Risk of HIV

HIV Clinical Trial

Official title:

Defining the Rectal Mucosa in Men Who Have Sex With Men at Risk of HIV Infection

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02401230
• Other study ID #: IRB00077593
• Status: Completed
• Phase: Phase 4
• First received: March 24, 2015
• Last updated: January 22, 2018
• Start date: March 2015
• Est. completion date: January 25, 2017

Study information

• Verified date: December 2017
• Source: Emory University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether the use of rectal lubricants can affect how well the medication, Truvada, will work to prevent infection with HIV when someone is exposed to HIV in the rectum.

Description:

Men who have sex with men (MSM) continue to be disproportionately affected by HIV. The majority of HIV infections among MSM occur through exposure to the rectal mucosa during receptive anal intercourse (RAI). During RAI, many MSM will use lubricants, which can potentially cause mucosal inflammation and damage. A new HIV prevention intervention, called pre-exposure prophylaxis (PrEP), recommends that MSM at risk of HIV infection take a daily anti-HIV medication called Truvada (tenofovir/emtricitabine) which is highly effective. However, it is not known if the use of lubricant during RAI will interfere with the efficacy of PrEP for HIV prevention.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 86
• Est. completion date: January 25, 2017
• Est. primary completion date: January 25, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 49 Years

Eligibility

Inclusion Criteria:

• HIV-negative man who reports receptive anal sex with another man in the last 6 months aged 18-49 years

• Male to female transgender women who are not currently taking hormonal therapy or plan to take hormonal therapy for the duration of the study

• Not currently taking pre-exposure prophylaxis (PrEP) and no plans to initiate during study

• Able to provide informed consent in English

• No plans for relocation in the next 6 months

• Willing to undergo peripheral blood and rectal biopsy sampling

• Willing to use study products as directed

• Willing to abstain from receptive anal intercourse 3 days prior to study visit 2 (4-16 weeks after the screening visit)and 10 days prior to study visit 4 (5-26 weeks after the screening visit)

• Willing to abstain from receptive anal intercourse for 1 week after study visit 2 (4-16 weeks after the screening visit) and study visit 4 (5-26 weeks after the screening visit)

Exclusion Criteria:

• History of inflammatory bowel disease or other inflammatory, infiltrative, infectious or vascular condition involving the lower gastrointestinal tract that, in the judgment of the investigators, may be worsened by study procedures or may significantly distort the anatomy of the distal large bowel

• Significant laboratory abnormalities at baseline visit for rectal biopsies, including but not limited to:

1. Hemoglobin (Hbg) = 10 g/dL

2. Partial thromboplastin time (PTT) > 1.5x upper limit normal (ULN) or international normalized ratio (INR) > 1.5x ULN

3. Platelet count <100,000

• Any known medical condition that, in the judgment of the investigators, increases the risk of local or systemic complications of endoscopic procedures or pelvic examination, including but not limited to:

1. Uncontrolled or severe cardiac arrhythmia

2. Recent major abdominal, cardiothoracic, or neurological surgery

3. History of uncontrolled bleeding diathesis

4. History of colonic, rectal, or vaginal perforation, fistula, or malignancy

5. History or evidence on clinical examination of ulcerative, suppurative, or proliferative lesions of the anorectal or vaginal mucosa, or untreated sexually transmitted disease with mucosal involvement

• Continued need for, or use during the 14 days prior to enrollment, of the following medications:

1. Aspirin or more than 4 doses of nonsteroidal anti-inflammatory drugs (NSAIDs)

2. Warfarin, heparin (low-molecular weight or unfractionated), platelet aggregation inhibitors, or fibrinolytic agents

3. Any form of rectally administered agent besides products lubricants or douching used for sexual intercourse

• Continued need for, or use during the 90 days prior to enrollment, of the following medications:

1. Systemic immunomodulatory agents

2. Supraphysiologic doses of steroids

3. Experimental medications, vaccines, or biologicals

• Intent to use HIV antiretroviral PrEP during the study, outside of the study procedures

• Symptoms of an untreated rectal sexually transmitted infection (e.g. rectal pain, discharge, bleeding, etc.)

• Current use of hormonal therapy

• Any other clinical condition or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for the study or unable to comply with the study requirements

Related Conditions & MeSH terms

• HIV

Intervention

Drug:
• Truvada
Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.

Device:
• Gel lubricant
Five ml of an over the counter sexual lubricant will be dispensed using an applicator.

Locations

Country	Name	City	State
United States	The Hope Clinic of of Emory University	Decatur	Georgia

Sponsors (2)

Lead Sponsor	Collaborator
Emory University	Centers for Disease Control and Prevention

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Median Percentage of CD4 Positive T-Cells	HIV target cell availability will be assessed by the median percentage of CD4+ T cells that express HIV co-receptor CCR5 as measured prior to product use and on day 8 after product use.	Baseline, Post-Intervention (Day 8)
Primary	Median Cumulative Amount of p24	The median cumulative amount of p24 produced in a rectal explant challenge assay as measured by ELISA from participants prior to product use and on day 8 after product use.	Baseline, Post-Intervention (Day 8)
Secondary	Median Plasma Emtricitabine (FTC) Concentration	Median plasma FTC concentration as measured in ng/ml prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.	Post-Intervention (Day 8)
Secondary	Median Plasma Tenofovir (TDF) Concentration	Median plasma TDF concentration as measured in ng/ml prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.	Post-Intervention (Day 8)
Secondary	Median Rectal Secretion Emtricitabine (FTC) Concentration	Median rectal secretions FTC concentrations as measured in ng/swab prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.	Post-Intervention (Day 8)
Secondary	Median Rectal Secretion Tenofovir (TDF) Concentration	Median rectal secretions TDF concentrations as measured in ng/swab prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.	Post-Intervention (Day 8)
Secondary	Median Peripheral Blood Mononuclear Cell (PBMC) Emtricitabine (FTC) Concentration	Median blood PBMC FTC concentrations as measured in fmol/million cells prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.	Post-Intervention (Day 8)
Secondary	Median Peripheral Blood Mononuclear Cell (PBMC) Tenofovir (TDF) Concentration	Median blood PBMC TDF concentrations as measured in fmol/million cells prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.	Post-Intervention (Day 8)
Secondary	Median Rectal Tissue Emtricitabine (FTC) Concentration	Median rectal tissue FTC concentrations as measured in fmol/mg tissue prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.	Post-Intervention (Day 8)
Secondary	Median Rectal Tissue Tenofovir (TDF) Concentration	Median rectal tissue TDF concentrations as measured in fmol/mg tissue prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.	Post-Intervention (Day 8)
Secondary	Median Rectal Tissue Deoxyadenosine Triphosphate (dATP) Concentration	Median rectal tissue dATP concentrations as measured in fmol/mg tissue prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.	Baseline, Post-Intervention (Day 8)
Secondary	Median Rectal Tissue Deoxycytidine Triphosphate (dCTP) Concentration	Median rectal tissue dCTP concentrations as measured in fmol/mg tissue prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.	Baseline, Post-Intervention (Day 8)
Secondary	Median Peripheral Blood Mononuclear Cell (PBMC) Deoxyadenosine Triphosphate (dATP) Concentration	Median blood dATP concentrations as measured in fmol/million cells prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.	Baseline, Post-Intervention (Day 8)